HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 overexpression	Solid Tumor	HER-2 overexpression	Solid Tumor	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
EGFR mutation	Solid Tumor	EGFR mutation	Solid Tumor	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2
HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 positive	Esophageal Cancer	HER-2 positive	Esophageal Cancer	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 rearrangement	Solid Tumor	HER-2 rearrangement	Solid Tumor	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER2 exon 20 mutation inhibitor Sensitive: C3 – Early Trials HER2 exon 20 mutation inhibitor Sensitive : C3	HER2 exon 20 mutation inhibitor Sensitive: C3 – Early Trials HER2 exon 20 mutation inhibitor Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	sevabertinib Sensitive: C3 – Early Trials sevabertinib Sensitive : C3	sevabertinib Sensitive: C3 – Early Trials sevabertinib Sensitive : C3

HER2 exon 20 mutation inhibitor

HER2 exon 20 mutation inhibitor

Associations(18)

Associations
(18)